Scinai shifts R&D focus to NanoAb platform, targets €12 million Poland grant for IL-17 psoriasis program

Scinai shifted R&D spending to its NanoAb platform, ending further funding commitments tied to the PC111 program.

Capital allocation will prioritize NanoAb development, partnering options, and non-dilutive financing, while preserving management capacity for CDMO execution.

Two IL-17 NanoAb programs remain core near-term priorities, including a psoriasis grant bid seeking EUR 12 million to reach first-in-human readiness.

CDMO growth stays central, targeting about USD 5 million of 2026 revenue, supported by about USD 3.1 million of committed orders.

Work began on an expanded U.S. customer clinical manufacturing and CMC program, with a broader definitive agreement targeted in coming weeks.